title: Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.
abstract: Therapeutic targeting of tumours on the basis of molecular analysis is a new paradigm for cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted therapeutics, such as inhibitors of oncogenic kinase pathways, elicit predominantly disease-stabilizing, cytostatic responses, rather than tumour regression. Combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, such as the BH3 mimetic ABT-737, may unlock potent anti-tumour potential to produce durable clinical responses with less collateral damage.
authors.affiliation: The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Victoria, Australia. msc@soton.ac.uk
authors.forename: Mark S
authors.initials: MS
authors.lastname: Cragg
authors.forename: Claire
authors.initials: C
authors.lastname: Harris
authors.forename: Andreas
authors.initials: A
authors.lastname: Strasser
authors.forename: Clare L
authors.initials: CL
authors.lastname: Scott